Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
Status:
Recruiting
Trial end date:
2022-04-04
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or
refractory acute myeloid leukemia or myelodysplastic syndrome. The purpose of this phase 1
study is to see how safe and tolerable the study drug is and to determine the best dose
(maximum tolerated dose or recommended phase 2 dose) that can be given in this patient
population.